Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
about
Targeting histone methyltransferases and demethylases in clinical trials for cancer therapyRecent progress toward epigenetic therapies: the example of mixed lineage leukemiaCancer epigenetics drug discovery and development: the challenge of hitting the markPotent inhibition of DOT1L as treatment of MLL-fusion leukemiaDOT1L inhibition sensitizes MLL-rearranged AML to chemotherapyLineage of origin in rhabdomyosarcoma informs pharmacological responseMurine models of acute leukemia: important tools in current pediatric leukemia research.The Biochemical Properties and Functions of CALM and AP180 in Clathrin Mediated Endocytosis.The molecular mechanics of mixed lineage leukemia.Primary acute myeloid leukemia cells with IDH1 or IDH2 mutations respond to a DOT1L inhibitor in vitroAF10 regulates progressive H3K79 methylation and HOX gene expression in diverse AML subtypes.Nuclear export signal within CALM is necessary for CALM-AF10-induced leukemiaSelective inhibitors of protein methyltransferasesNovel agents for the treatment of childhood acute leukemia.DOT1L inhibits SIRT1-mediated epigenetic silencing to maintain leukemic gene expression in MLL-rearranged leukemia.Targeting DOT1L and HOX gene expression in MLL-rearranged leukemia and beyondThe histone methyltransferase DOT1L: regulatory functions and a cancer therapy target.Treatment of infant leukemias: challenge and promise.MLL-AF9- and HOXA9-mediated acute myeloid leukemia stem cell self-renewal requires JMJD1C.Leukemic transformation by the MLL-AF6 fusion oncogene requires the H3K79 methyltransferase Dot1l.MLL1 and DOT1L cooperate with meningioma-1 to induce acute myeloid leukemiaTargeted drug discovery for pediatric leukemia.The histone methyltransferase Dot1/DOT1L as a critical regulator of the cell cycle.The role of chromatin modifiers in normal and malignant hematopoiesisNovel therapies for children with acute myeloid leukaemia.Proof-of-concept rare cancers in drug development: the case for rhabdomyosarcoma.Regulatory variation: an emerging vantage point for cancer biology.Epigenetic modifications in pediatric acute lymphoblastic leukemia.Epigenetics in T-cell acute lymphoblastic leukemia.Molecular mechanisms of MLL-associated leukemia.Emerging therapeutic targets in human acute myeloid leukemia (part 2) - bromodomain inhibition should be considered as a possible strategy for various patient subsets.Epigenetic modifiers in normal and malignant hematopoiesis.Novel approaches to pediatric leukemia treatment.Emerging therapeutic drugs for AML.Inhibitors of Protein Methyltransferases and Demethylases.Marked for death: targeting epigenetic changes in cancer.The PZP Domain of AF10 Senses Unmodified H3K27 to Regulate DOT1L-Mediated Methylation of H3K79.Preclinical Pharmacokinetics and Pharmacodynamics of Pinometostat (EPZ-5676), a First-in-Class, Small Molecule S-Adenosyl Methionine Competitive Inhibitor of DOT1L.The development of targeted new agents to improve the outcome for children with leukemia.A critical role for CRM1 in regulating HOXA gene transcription in CALM-AF10 leukemias.
P2860
Q26746038-DABCEE8C-F9DB-4075-AA8D-88F97FB6CA6BQ26863577-54D50254-788C-4162-A0FD-55DF8CBC4CCCQ27002333-DA6FC4F5-76D6-4E01-B65A-CD1E1552F9AFQ27678800-70315642-BC9D-4720-AC20-335FA3BB5567Q28539096-F1E59DF9-4373-4581-BB03-F8375ADCE4BCQ30411722-483F4FE8-9561-4B40-9FD4-CDCA240181ECQ33606018-3D6EE0ED-9641-4C00-9398-765B0943917FQ34324323-C26FB34E-6884-4E70-8A62-56073754F1A6Q34516051-2EE904BC-981D-41FC-BA7C-39FC6E34A2A7Q34674381-B8F30B75-C361-4A6B-A544-ED10D63C272CQ34918857-406D15CB-1849-4C06-B48A-B99D90982F7BQ35051940-73B73AAF-40C5-4180-B098-3DA1FB09DD05Q35135783-4F0E169D-8A59-4C1B-9E1A-A6BFEDC3551DQ35192790-B195CF6E-A5CE-4887-A75C-A3BE2DED851CQ35329614-51970CC8-B6BC-4FCA-9F29-22AD1199BA5EQ35967446-792513A3-19BA-47F0-B32E-1C5F1258C4C6Q36250669-A79F3404-B8A8-4E39-8D44-890A195389BEQ36508988-7ED9245B-3726-4135-9ADB-384BF91D5A5BQ36618536-1C27A73E-EC67-4F26-B6AD-F028CDE0C1C5Q36730426-F4FC1B71-135D-4F03-8778-910BE013748AQ36737896-2DD28543-C1E8-4BFD-A8D3-08924B1B6B6AQ36989223-4B9D91F6-46D1-4C4E-BF08-16271FE503BCQ37692579-D0ABFFAE-BF8E-4C59-8731-3842F74B6E7AQ38071526-F8D1C834-FC43-44C8-85C2-5A49EA466475Q38096798-20118E6C-3095-4572-A044-A147B4D673FAQ38105879-68D9E97A-4387-4A34-A252-B26451CB7030Q38164307-41468855-E3FB-4B31-A4AB-8E1E0A919554Q38214773-84DD26DE-21D5-4E75-A1CA-50251F55E3A3Q38289023-9D0AEF98-910E-4505-AAD5-3C400B568FF8Q38379210-CFDF9E81-ADA8-4DC1-BBE3-DDCF53C91169Q38435352-287DA843-C720-4F53-9D35-C2EBC218B471Q38459868-50E56347-A5F1-4094-8CCD-33B4B25975C3Q38500371-CFC4F91E-50C4-422E-91D4-6B30CC029B48Q38667491-33F65EBD-7069-42AD-8CA7-1F02600BFC64Q38740496-C3A6AD97-1156-408D-A09C-87433D147537Q38747872-7B58DC43-80E7-4A4F-A577-A789FF66FDB0Q38830100-3F94E119-17A2-4F44-81EF-691A68BE638FQ38946966-0B18F3A9-6928-41D0-AB0C-AAB63EDD0665Q38964974-688B963C-036D-40B0-A6CA-89E013E52BFEQ38975042-9A1A4936-14B7-4037-BE5E-C0CB60A2CEF3
P2860
Abrogation of MLL-AF10 and CALM-AF10-mediated transformation through genetic inactivation or pharmacological inhibition of the H3K79 methyltransferase Dot1l.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Abrogation of MLL-AF10 and CAL ...... H3K79 methyltransferase Dot1l.
@en
Abrogation of MLL-AF10 and CAL ...... H3K79 methyltransferase Dot1l.
@nl
type
label
Abrogation of MLL-AF10 and CAL ...... H3K79 methyltransferase Dot1l.
@en
Abrogation of MLL-AF10 and CAL ...... H3K79 methyltransferase Dot1l.
@nl
prefLabel
Abrogation of MLL-AF10 and CAL ...... H3K79 methyltransferase Dot1l.
@en
Abrogation of MLL-AF10 and CAL ...... H3K79 methyltransferase Dot1l.
@nl
P2093
P2860
P356
P1433
P1476
Abrogation of MLL-AF10 and CAL ...... H3K79 methyltransferase Dot1l
@en
P2093
A J Deshpande
E J Olhava
R M Pollock
S A Armstrong
S R Daigle
V M Richon
P2860
P2888
P304
P356
10.1038/LEU.2012.327
P577
2012-11-09T00:00:00Z